Showing results (151-160 of 220) with videos related to
Sort By:
Pageof 22
Expert Opinion on Drug Safety|April 21, 2015
Are we waiting too long for the cardiovascular outcome trials with the glucagon-like peptide-1 receptor agonists?Sheila A DoggrellExpert Opinion on Pharmacotherapy|October 6, 2006
Recent evidence of sustained benefit with exenatide in Type 2 diabetesSheila A DoggrellExpert Opinion on Pharmacotherapy|February 16, 2005
Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunctionSheila A DoggrellExpert Opinion on Pharmacotherapy|February 16, 2005
Fluoxetine--do the benefits outweigh the risks in adolescent major depression?Sheila A DoggrellExpert Opinion on Investigational Drugs|June 24, 2004
Sarpogrelate: cardiovascular and renal clinical potentialSheila A DoggrellExpert Opinion on Investigational Drugs|April 23, 2004
Do vasopressin receptor type 2 antagonists have therapeutic potential in polycystic kidney diseases?Sheila A DoggrellExpert Opinion on Therapeutic Targets|May 27, 2004
The endothelin system and its role in acute myocardial infarctionSheila A DoggrellExpert Opinion on Pharmacotherapy|December 4, 2003
Recurrent hope for the treatment of preterm deliverySheila A DoggrellExpert Opinion on Investigational Drugs|October 27, 2004
A neuroprotective derivative of erythropoietin that is not erythropoieticSheila A DoggrellCurrent Opinion in Investigational Drugs (London, England : 2000)|October 27, 2004
ETC-588 (Pfizer)Sheila A DoggrellPageof 22